Latest Diagnostic Imaging News

Integral Diagnostics (IDX) reported a robust FY25 with 33.7% revenue growth and operating EBITDA margin expansion, driven by the Capitol merger and organic growth. The company exceeded synergy expectations and outlined a confident outlook amid favourable industry tailwinds.

Integral Diagnostics posts robust FY25 results with strong revenue growth and merger synergies exceeding expectations, setting a confident tone for FY26.

Integral Diagnostics Limited (ASX – IDX) reported a robust FY25 performance, boosted by its transformative merger with Capitol Health Limited. The company posted strong revenue and profit growth, declared a 4.0 cent final dividend, and outlined strategic priorities including AI adoption and teleradiology expansion.

333D Limited reported a 12% increase in quarterly cash receipts from digital asset management contracts, maintaining steady cash flow despite slight operating cash usage. The company’s annual contract revenue surpassed $970,000, reflecting growing traction in healthcare digital services.

Clarity Pharmaceuticals has successfully completed recruitment for its pivotal Co-PSMA Phase II trial, testing its novel Cu-SAR-bisPSMA diagnostic against the current standard in detecting prostate cancer recurrence. This milestone advances their mission to improve early detection and treatment outcomes for men with low PSA levels.

Telix Pharmaceuticals showcased its global theranostic radiopharmaceutical portfolio, highlighting FDA approvals, clinical progress, and a robust commercial expansion plan at its 2025 Investor Day.

Clarity Pharmaceuticals has successfully imaged the first patient in its pivotal Phase III AMPLIFY trial for Cu-SAR-bisPSMA, a next-generation diagnostic agent targeting recurrent prostate cancer. This milestone sets the stage for potential FDA approval and broader clinical adoption.

Pro Medicus Limited’s U.S. subsidiary, Visage Imaging, has landed a significant five-year, A$20 million contract to implement its cloud-based Visage 7 imaging platform at University of Iowa Health Care, marking a major step in cloud adoption for healthcare IT.

4DMedical has landed a significant commercial contract with Intermountain Health to deploy its FDA-cleared Pulmonary Hypertension Analysis (PHA™) product, marking a key milestone in its U.S. expansion through a strategic Microsoft-backed partnership.

Artrya Limited has launched a A$15 million capital raising to fund the development and commercial rollout of its Salix AI-powered coronary artery disease diagnostic platform, targeting the lucrative US healthcare market.

Artrya has secured a pivotal three-year commercial contract with Sonic Healthcare Australia to deploy its AI-driven Salix Coronary Anatomy platform across over 125 radiology centres, marking a significant step in commercialising its coronary artery disease diagnostic technology.

Clarity Pharmaceuticals has expanded its breast cancer pipeline by introducing 64/67Cu-SAR-trastuzumab, supported by promising pre-clinical data and a new supply agreement for trastuzumab, aiming to address the unmet needs in HER2-positive breast cancer treatment.